NCT01160952 is a Phase 2 clinical trial of itraconazole in Hematological Diseases, sponsored by Guangzhou General Hospital of Guangzhou Military Command.

Who is sponsoring NCT01160952?

NCT01160952 is sponsored by Guangzhou General Hospital of Guangzhou Military Command.

What drugs are being tested in NCT01160952?

Interventions in NCT01160952: itraconazole.

What condition does NCT01160952 study?

NCT01160952 studies Hematological Diseases, Allogeneic Stem Cell Transplantation.

Is NCT01160952 still recruiting?

NCT01160952 is currently status unknown. Last updated 23 July 2010.

Last reviewed 2010-07-23 · How we verify

NCT01160952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation

Status unknown Phase 2 Last updated 23 July 2010

What this trial tests

Phase 2 trial testing itraconazole in Hematological Diseases in 120 participants. Status unknown.

Timeline

1 May 2009

Primary endpoint
1 December 2010

1 March 2011

Quick facts

Lead sponsor	Guangzhou General Hospital of Guangzhou Military Command
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	120
Start date	1 May 2009
Primary completion	1 December 2010
Estimated completion	1 March 2011
Sites	1 location across China

Drugs / interventions tested

itraconazole — full drug profile →

Conditions studied

Hematological Diseases — all drugs for Hematological Diseases →
Allogeneic Stem Cell Transplantation — all drugs for Allogeneic Stem Cell Transplantation →

Sponsor

Guangzhou General Hospital of Guangzhou Military Command

Who can join

Adults 14 to 60, any sex, with Hematological Diseases or Allogeneic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

efficacy evaluation
Time frame: 90 days
the success rate of prophylaxis therapy by itraconazole

Sponsor's own description

* The primary objective of this study is to evaluate the efficacy and safety profile of itraconazole as in primary prophylaxis * The second objective of this study is to find the difference between long-term versus short-term sequential therapy of Itraconazole (intravenous followed by oral itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients undergoing allogeneic stem cell transplantation (allo-SCT) * also to explore the relationship between the incidence of IFI with plasma concentrations of itraconazole and hydroxy-itraconazole

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013
· 2013

Verify or expand the search:

Other trials of itraconazole

Trials testing the same drug.

NCT07357610 — An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healt · Phase 1 · recruiting
NCT06909162 — A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itr · Phase 1 · recruiting
NCT06041438 — A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood · Phase 1 · completed
NCT05578950 — Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment · Phase 1 · completed
NCT05129033 — A Prospective Study on Optimizing Treatment for ABPA · NA · unknown

Other recruiting trials for Hematological Diseases

Currently open trials in the same condition.

NCT06281496 — AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation · NA · recruiting
NCT05329649 — Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) · Phase 3 · active not recruiting

Other Guangzhou General Hospital of Guangzhou Military Command trials

Trials by the same sponsor.

NCT07462949 — A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhi · NA · completed
NCT07145697 — The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness · Phase 4 · recruiting
NCT05187455 — Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantat · Phase 4 · unknown
NCT05202899 — Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniot · Phase 4 · unknown
NCT04794673 — Cortex Motor Function Reorganization in Stroke Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01160952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou General Hospital of Guangzhou Military Command
Last refreshed: 23 July 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01160952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing